First-in-Human Safety, Tolerability, and Pharmacokinetics of Single-Dose Kukoamine B Mesylate in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase I Study

ConclusionsSingle-dose KB demonstrated favorable safety and tolerability in healthy subjects at the dose level of 0.005 –0.48 mg/kg. KB exhibited a non-linear pharmacokinetic profile with a half-life of about 1.61–4.24 h, which mainly distributed in plasma.Trial RegistrationClinicalTrials.gov identifier, NCT02219971.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research